Medtronic's stock has lost around a third of its value since late 2022. However, stock prices for longtime dividend growers ...
Medtronic (NYSE:MDT) shares snapped seven straight days of losses as the stock closed 0.85% higher, at $88.98 on Thursday. ...
The recall, which affects two models of Pipeline Vantage embolization devices, is linked to 17 injuries and four deaths.
Medtronic’s diverse portfolio faces financial growth concerns. Learn why MDT stock is a HOLD, offering stability but limited growth in the short term.
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
Medtronic’s top ventilator executive began fielding pleas from world leaders' representatives five years ago, as pressure ...
The FDA deemed a recall of some Medtronic Pipeline Vantage embolization devices serious after multiple deaths related to the ...
Medtronic's recall of embolization device has been classified most serious by the U.S. Food and Drug Administration (USFDA), ...
Medical Device Network on MSN9d
FDA tags Medtronic embolisation device recall as Class IThe US Food and Drug Administration (FDA) has tagged Medtronic’s recall of certain Pipeline Vantage embolisation devices as ...
Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...
The FDA recall affects more than 25,000 of the Fridley-run company’s devices and follows reports of 17 injuries.
Medtronic plc (NYSE:MDT – Get Free Report) has received a consensus rating of “Hold” from the sixteen ratings firms that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback